The therapeutic implications of ketone bodies: The effects of ketone bodies in pathological conditions: Ketosis, ketogenic diet, redox states, insulin resistance, and mitochondrial metabolism

Prostaglandins Leukotrienes and Essential Fatty Acids

Volumn 70, Issue 3, 2004, Pages 309-319

  Veech, Richard L ^a  

^a Med Officer Biodefense Clin R   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 HYDROXYBUTYRIC ACID; ACYL COENZYME A DEHYDROGENASE; ADENOSINE TRIPHOSPHATE; DIALYSIS FLUID; FATTY ACID; FREE RADICAL; FUEL; KETONE BODY; MITOCHONDRIAL PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PYRUVIC ACID;

ADVANCED CANCER; ASTROCYTOMA; CANCER CHEMOTHERAPY; DEGENERATIVE DISEASE; ENZYME DEFICIENCY; EPILEPSY; FATTY ACID METABOLISM; GENETIC DISORDER; GLYCOLYSIS; HUMAN; HYDROLYSIS; HYPOGLYCEMIA; HYPOXIA; INSULIN RESISTANCE; KETOACIDOSIS; KETOGENIC DIET; MITOCHONDRIAL RESPIRATION; MUSCLE ATROPHY; MYOPATHY; NONHUMAN; OXIDATION REDUCTION STATE; PRIORITY JOURNAL; REVIEW; TUMOR; WEIGHT REDUCTION;

EID: 1042299789     PISSN: 09523278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.plefa.2003.09.007     Document Type: Article

References (76)

1. Y. Kashiwaya, K. Sato, N. Tsuchiya, S. Thomas, D.A. Fell, R.L. Veech, et al., Control of glucose utilization in working perfused rat heart, J. Biol. Chem. 269 (1994) 25502-25514.
2. K. Sato, Y. Kashiwaya, C.A. Keon, N. Tsuchiya, M.T. King, G.K. Radda, et al., Insulin, ketone bodies, and mitochondrial energy transduction, FASEB J. 9 (1995) 651-658.
3. D.F. Horrobin, Innovation in the pharmaceutical industry, J.R. Soc. Med. 93 (7) (2000) 341-345.
4. H.A. Krebs, R.L. Veech, Pyridine nucleotide interrelations, in: S. Papa, J.M. Tager, E. Quagliariello, E.C. Slater (Eds.), The Energy Level and Metabolic Control in Mitochondria, Bari, Adriatica Editrice, 1969, pp. 329-382.
5. W.M. Clark, Oxidation Reduction Potentials of Organic Systems, Williams and Wilkins Co., Baltimore, 1960.
6. P. Mitchell, Chemiosmotic Coupling and Energy Transduction, Glynn Research Ltd., Bodmin, 1968.
7. C. Gibbons, M.G. Montgomery, A.G.W. Leslie, J.E. Walker, The structure of the central stalk in bovine F1-ATPase at 2.4A resolution, Nature Struct. Biol. 7 (2000) 1055-1061.
8. K. Yasuda, H. Noji, K. Kinosita Jr., M. Yoshida, F1-ATPase is a highly efficient molecular motor that rotates with discrete 120° steps, Cell 93 (1998) 1117-1124.
9. D.H. Williamson, P. Lund, H.A. Krebs, The redox state of free nicotinamide-adenine dinucleotide in the cytoplasm and mitochondria of rat liver, Biochem. J. 103 (1967) 514-527.
10. E.A. Boehm, B.E. Jones, G.K. Radda, R.L. Veech, K. Clarke, Increased uncoupling proteins and decreased efficiency in palmitate-perfused hyperthyroid rat heart, Am. J. Physiol Heart Circ. Physiol 280 (3) (2001) H977-H983.
11. O.E. Owen, A.P. Morgan, H.G. Kemp, J.M. Sullivan, M.G. Herrera, G.F. Cahill Jr., Brain metabolism during fasting, J. Clin. Invest. 46 (1967) 1589-1595.
12. G.F. Cahill Jr., Starvation in man, N. Engl. J. Med. 282 (1970) 668-675.
13. G.F. Cahill Jr., M.G. Herrera, A.P. Morgan, J.S. Soeldner, J. Steinke, P.L. Levy, et al., Hormone-fuel interrelationships during fasting, J. Clin. Invest 45 (11) (1966) 1751-1769.
14. J.P. Casazza, M.E. Felver, R.L. Veech, The metabolism of acetone in rat, J. Biol. Chem. 259 (1984) 231-236.
15. T.B. Vanltallie, T.H. Nufert, Ketones: metabolism's "Ugly Duckling", Annu. Rev. Nutr. 61 (10) (2003) 327-341.
16. G.A. Reichard, O.E. Owen, A.C. Haff, P. Paul, W.M. Bortz, Ketone-body production and oxidation in fasting obese humans, J. Clin. Invest. 53 (2) (1974) 508-515.
17. R.L. Leino, D.Z. Gerhart, R. Duelli, B.E. Enerson, L.R. Drewes, Diet-induced ketosis increases monocarboxylate transporter (MCT1) levels in rat brain, Neurochem. Int. 38 (6) (2001) 519-527.
18. B. Chance, H. Sies, A. Boveris, Hydroperoxide metabolism in mammalian organs, Physiol. Rev. 59 (3) (1979) 527-605.
19. R.L. Veech, L.V. Eggleston, H.A. Krebs, The redox state of free nicotinamide-adenine dinucleotide phosphate in the cytoplasm of rat liver, Biochem. J. 115 (1969) 609-619.
20. R.L. Veech, B. Chance, Y. Kashiwaya, H.A. Lardy, G.F. Cahill Jr., Ketone bodies, potential therapeutic uses, IUBMB Life 51 (4) (2001) 241-247.
21. J.M. Freeman, E.P.G. Vining. Intractable epilepsy, Epilepsia 33 (1992) 1132-1136.
22. S.L. Kinsman, E.P. Vining, S.A. Quaskey, D. Mellits, J.M. Freeman, Efficacy of the ketogenic diet for intractable seizure disorders: review of 58 cases, Epilepsia 33 (6) (1992) 1132-1136.
23. D.L. Gilbert, P.L. Pyzik, J.M. Freeman, The ketogenic diet: seizure control correlates better with serum beta-hydroxybutyrate than with urine ketones, J. Child Neurol. 15 (12) (2000) 787-790.
24. M. Erecinska, D. Nelson, Y, Daikhin, M. Yudkoff, Regulation of GABA level in rat brain synaptosomes: fluxes through enzymes of the GABA shunt and effects of glutamate, calcium, and ketone bodies, J. Neurochem. 67 (6) (1996) 2325-2334.
25. M. Yudkoff, Y. Daikhin, I. Nissim, R. Grunstein, Effects of ketone bodies on astrocyte amino acid metabolism, J. Neurochem. 69 (2) (1997) 682-692.
26. A.E. Greene, M.T. Todorova, R. McGowan, T.N. Seyfried, Caloric restriction inhibits seizure susceptibility in epileptic EL mice by reducing blood glucose, Epilepsia 42 (11) (2001) 1371-1378.
27. R.L. Veech, Y, Kashiwaya, D.N. Gates, M.T. King, K. Clarke, The energetics of ion distribution: the origin of the resting electric potential of cells, IUBMB Life 54 (2002) 241-252.
28. P.R. Huttenlocher, A.J. Wilbourn, J.M. Signore, Medium-chain triglycerides as a therapy for intractable childhood epilepsy, Neurology 21 (11) (1971) 1097-1103.
29. C.A. Dell, S.S. Likhodii, K. Musa, M.A. Ryan, W.M. Burnham, S.C. Cunnane, Lipid and fatty acid profiles in rats consuming different high-fat ketogenic diets, Lipids 36 (4) (2001) 373-378.
30. T.H. Best, D.N. Franz, D.L. Gilbert, D.P. Nelson, M.R. Epstein, Cardiac complications in pediatric patients on the ketogenic diet, Neurology 54 (12) (2000) 2328-2330.
31. S. Kielb, H.P. Koo, D.A. Bloom, G.J. Faerber, Nephrolithiasis associated with the ketogenic diet, J. Urol. 164 (2) (2000) 464-466.
32. G. Taubes, What if its all been a Big Fat Lie? Sect. Magazine, NY Times, 2002.
33. E.C. Westman, W.S. Yancy, J.S. Edman, K.F. Tomlin, C.E. Perkins, Effect of 6-month adherence to a very low carbohydrate diet program, Am. J. Med. 113 (1) (2002) 30-36.
34. S.A. Beck, M.J. Tisdale, Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice, Cancer Res. 49 (14) (1989) 3800-3804.
35. L.C. Nebeling, E. Lerner, Implementing a ketogenic diet based on medium-chain triglyceride oil in pediatric patients with cancer, J. Am. Diet. Assoc. 95 (6) (1995) 693-697.
36. L.C. Nebeling, F. Miraldi, S.B. Shurin, E. Lerner, Effects of a ketogenic diet on tumor metabolism and nutritional status in pediatric oncology patients: two case reports, J. Am. Coll. Nutr. 14 (2) (1995) 202-208.
37. P. Mukherjee, M.M. El Abbadi, J.L. Kasperzyk, M.K. Ranes, T.N. Seyfried, Dietary restriction reduces angiogenesis and growth in an orthotopic mouse brain tumour model, Br. J. Cancer 86 (10) (2002) 1615-1621.
38. R.L. Veech, The toxic impact of parenteral solutions on the metabolism of cells: a hypothesis for physiological parenteral therapy, Am. J. Clin. Nutr. 44 (1986) 519-551.
39. Fluid Resuscitation: State of the Science for Treating Combat Casualties and Civilian Injuries, National Academy Press, Washington DC, 1999.
40. H.B. Alam, B. Austin, E. Koustova, P. Rhee, Resuscitation-induced pulmonary apoptosis and intracellular adhesion molecule-1 expression in rats are attenuated by the use of Ketone Ringer's solution, J. Am. Coll. Surg. 193 (3) (2001) 255-263.
41. L. Chan, J. Slater, J. Hasbargen, D.N. Herndon, R.L. Veech, S. Wolf, Neurocardiac toxicity of racemic D,L-lactate fluids, Integr. Physiol. Behav. Sci. 29 (1994) 383-394.
42. J.L. Van Hove, S. Grunewald, J. Jaeken, P. Demaerel, P.E. Declercq, P. Bourdoux, et al., D,L-3-hydroxybutyrate treatment of multiple acyl-CoA dehydrogenase deficiency (MADD). Lancet 361 (9367) (2003) 1433-1435.
43. Y. Kashiwaya, M.T. King, R.L. Veech, Substrate signaling by insulin: a ketone bodies ratio mimics insulin action in heart. Am. J. Cardiol. 80 (3A) (1997) 50A-64A.
44. P. Bjorntorp, G. Holm, R. Rosmond, B. Folkow, Hypertension and the metabolic syndrome: closely related central origin? Blood Pressure 9 (2-3) (2000) 71-82.
45. F. Lomeo, M.A. Khokher, P. Dandona, Ethanol and its novel metabolites inhibit insulin action on adipocytes, Diabetes 37 (7) (1988) 912-915.
46. D. Xu, A.S. Dhillon, A. Abelmann, K. Croft, T.J. Peters, T.N. Palmer, Alcohol-related diols cause acute insulin resistance in vivo, Metabolism 47 (10) (1998) 1180-1186.
47. P. Roach, Y. Zick, P. Formisano, D. Accili, S.I. Taylor, P. Gorden, A novel human insulin receptor gene mutation uniquely inhibits insulin binding without impairing posttranslational processing, Diabetes 43 (9) (1994) 1096-1102.
48. C.A. Bondy, L.E. Underwood, D.R. Clemmons, H.P. Guler, M.A. Bach, M. Skarulis, Clinical uses of insulin-like growth factor I [see comments], Ann. Intern. Med. 120 (7) (1994) 593-601.
49. S.J. Vannucci, F. Maher, I.A. Simpson, Glucose transporter proteins in brain: delivery of glucose to neurons and glia, Glia 21 (1) (1997) 2-21.
50. D.C. De Vivo, L. Leary, D. Wang, Glucose transporter 1 deficiency syndrome and other glycolytic defects, J. Child Neurol. 17 (Suppl 3) (2002) 3S15-23 (discussion 3S24-5:3S15-23).
51. G.F. Cahill Jr., T.T. Aoki, Alternate fuel utilization in brain, in: J.V. Passonneau. R.A. Hawkins, W.D. Lust, F.A. Welsh (Eds.), Cerebral Metabolism and Neural Function, Williams & Wilkins, Baltimore, 1980, pp. 234-242.
52. P.N. Ainslie, I.T. Campbell, K.N. Frayn, S.M. Humphreys, D.P. MacLaren, T. Reilly, Physiological, metabolic, and performance implications of a prolonged hill walk: influence of energy intake, J. Appl. Physiol. 94 (3) (2003) 1075-1083.
53. B.J. Dardzinski, S.L. Smith, J. Towfighi, G.D. Williams, R.C. Vannucci, M.B. Smith, Increased plasma beta-hydroxybutyrate, preserved cerebral energy metabolism, and amelioration of brain damage during neonatal hypoxia ischemia with dexamethasone pretreatment, Pediatr. Res. 48 (2) (2000) 248-255.
54. M. Suzuki, M. Suzuki, K. Sato, S. Dohi, T. Sato, A. Matsuura, et al., Effect of beta-hydroxybutyrate, a cerebral function improving agent, on cerebral hypoxia, anoxia and ischemia in mice and rats, Jpn. J. Pharmacol. 87 (2) (2001) 143-150.
55. M. Beylot, D. Chassard, C. Chambrier, M. Guiraud, M. Odeon, B. Beaufrere, et al., Metabolic effects of a D-beta-hydroxybutyrate infusion in septic patients: inhibition of lipolysis and glucose production but not leucine oxidation, Crit. Care Med. 22 (7) (1994) 1091-1098.
56. S. Marcondes, I.V. Turko, F. Murad, Nitration of succinyl-CoA:3-oxoacid CoA-transferase in rats after endotoxin administration, Proc. Natl. Acad. Sci. USA 98 (13) (2001) 7146-7151.
57. S. Adinolfi, M. Trifuoggi, A.S. Politou, S. Martin, A. Pastore, A structural approach to understanding the iron-binding properties of phylogenetically different frataxins, Hum. Mol. Genet. 11 (16) (2002) 1865-1877.
58. M. Bunse, N. Bit-Avragim, A. Riefflin, A. Perrot, O. Schmidt, F.R. Kreuz, et al., Cardiac energetics correlates to myocardial hypertrophy in Friedreich's ataxia, Ann. Neurol. 53 (1) (2003) 121-123.
59. M. Ristow, M.F. Pfister, A.J. Yee, M. Schubert, L. Michael, C.Y. Zhang, et al., Frataxin activates mitochondrial energy conversion and oxidative phosphorylation [In Process Citation], Proc. Natl. Acad. Sci. USA 97 (22) (2000) 12239-12243.
60. J.W. Langston, E.B. Langston, I. Irwin, MPTP-induced parkinsonism in human and non-human primates - clinical and experimental aspects. Acta Neurol. Scand. Suppl. 100 (1984) 49-54.
61. J.D. Adams Jr., L.K. Klaidman, A.C. Leung, MPP+ and MPDP+ induced oxygen radical formation with mitochondrial enzymes. Free Radic. Biol. Med. 5 (2) (1993) 181-186.
62. Y. Kashiwaya, T. Takeshima, N. Mon, K. Nakashima, K. Clarke, R.L. Veech, D-beta-hydroxybutyrate protects neurons in models of Alzheimer's and Parkinson's disease, Proc. Natl. Acad. Sci. USA 97 (10) (2000) 5440-5444.
63. D.A. Evans, H.H. Funkenstein, M.S. Albert, P.A. Scherr, N.R. Cook, M.J. Chown, et al., Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported [see comments], J. Am. Med. Assoc. 262 (18) (1989) 2551-2556.
64. R.N. Kalaria, S.U. Bhatti, E.A. Palatinsky, D.H. Pennington, E.R. Shelton, H.W. Chan, et al., Accumulation of the beta amyloid precursor protein at sites of ischemic injury in rat brain, Neuroreport 4 (2) (1993) 211-214.
65. G. Kanayama, M. Takeda, H. Niigawa, Y. Ikura, H. Tamii, N. Taniguchi, et al., The effects of repetitive mild brain injury on cytoskeletal protein and behavior, Methods Find. Exp. Clin. Pharmacol. 18 (2) (1996) 105-115.
66. S. Seshadri, A. Beiser, J. Selhub, P.P. Jacques, I.H. Rosenberg. R.B. D'Agostino, et al., Plasma homocysteine as a risk factor for dementia and Alzheimer's disease, N. Engl. J. Med. 346 (7) (2002) 476-483.
67. J. Kuusisto, K. Koivisto, L. Mykkanen, F.L. Helkala, M. Vanhunen, K. Kervinen, et al., Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study, Brit. Med. J. 315 (1997) 1045-1049.
68. D. Gabuzda, J. Busciglio, L.B. Chen, P. Matsudaira, B.A. Yankner, Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative, J. Biol. Chem. 269 (1994) 13623-13628.
69. A. Pope, H.H. Hess, E. Lewin, Microchemical pathology of the cerebral cortex in presenile dementia. Trans. Am. Neurol. Assoc. 89 (1965) 15-16.
70. T.W. Robbins, G. McAlonan, J.L. Muir, B.J. Everitt, Cognitive enhancers in theory and practice: studies of the cholinergic hypothesis of cognitive deficits in Alzheimer's disease, Behav. Brain Res. 83 (1-2) (1997) 15-23.
71. Y.M. Kuo, M.R. Emmerling, C. Vigo-Pelfrey, T.C. Kasunic, J.B. Kirkpatrick, G.H. Murdoch, et al., Water-soluble Abeta (N-40, N-42] oligomers in normal and Alzheimer disease brains, J. Biol. Chem. 271 (8) (1996) 4077-4081.
72. M. Hoshi, M. Sato, S. Kondo, A. Takashima, K. Noguchi, M. Takahashi, et al., Different localization of tau protein kinase I/ glycogen synthase kinase-3 beta from glycogen synthase kinase-3 alpha in cerebellum mitochondria, J. Biochem. 118 (4) (1995) 683-685 (Tokyo).
73. M. Hoshi, A. Takashima, K. Noguchi, M. Murayama, M. Sato, S. Kondo, et al., Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain, Proc. Natl. Acad. Sci. USA 93 (7) (1996) 2719-2723.
74. 1-42 suppresses acetylcholine synthesis, J. Biol. Chem. 272 (4) (1997) 2038-2041.
75. H.M. Muller, D. Seebach, Poly(hydroxyalkanoates): a fifth class of physiologically important organic biopolyers. Angew. Chem. 32 (1994) 477-502.
76. D. Seebach, A. Brunner, H.M. Burger, J. Schneider, R.N. Reusch, Isolation and 1H-NMR spectroscopic identification of poly(3-hydroxybutanoate) from prokaryotic and eukaryotic organisms. Determination of the absolute configuration (R) of the monomeric unit 3-hydroxybutanoic acid from Escherichia coli and spinach. Eur. J. Biochem. 224 (2) (1994) 317-328.